KA-2237 is under clinical development by Karus Therapeutics and currently in Phase I for Mantle Cell Lymphoma. According to GlobalData, Phase I drugs for Mantle Cell Lymphoma have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how KA-2237’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
KA-2237 is under development for the treatment of haematological tumors, including relapsed or refractory B-cell lymphomas including diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia or small lymphocytic lymphoma and marginal zone b-cell lymphoma. It is administered through the oral route. The drug candidate acts by targeting both phosphoinositide 3-kinase (PI3K) isoforms such as p110 delta and beta. It was also under development for the treatment of inflammation and solid tumors. It was also under development for the treatment of Waldenstrom Macroglobulinemia .
Karus Therapeutics overview
Karus Therapeutics (Karus) operates as a drug development company that designs and develops cancer therapies. The company offers small molecule drugs with immunotherapy for the treatment of hematological and solid tumors. Its pipeline products include KA2507 and KA2237 inhibitors. Karus’ KA2507 is a highly selective inhibitor of HDAC6 for the treatment of multiple myeloma and inflammatory diseases. The company’s KA2237 is a dual selective inhibitor of P13K for the treatment of solid tumors and hematological cancers. Its development programs offer medical needs in the fields of chronic inflammation, retaining drug design, immunotherapeutic modes, haematological malignancies and solid tumours. Karus is headquartered in Oxford, the UK.
For a complete picture of KA-2237’s drug-specific PTSR and LoA scores, buy the report here.